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A growing body of research shows that human papil-
lomavirus (HPV) is a common and increasing cause of 
oropharyngeal squamous cell carcinoma (OSCC). Thus, 
the International Agency for Research against Cancer has 
acknowledged HPV as a risk factor for OSCC, in addition to 
smoking and alcohol consumption. Recently, in Finland, the 
United Kingdom, the Netherlands, the United States, and 
Sweden, incidence of OSCC has increased, and an increase 
in the proportion of HPV-positive tumors was noted. On the 
basis of these data and reports indicating that patients with 
HPV-positive cancer have their ﬁ  rst sexual experience at a 
young age and have multiple partners, we postulate that in-
creased incidence of OSCC in the United States and some 
countries in northern Europe is because of a new, primarily 
sexually transmitted HPV epidemic. We also suggest that 
individualized treatment modalities and preventive vaccina-
tion should be further explored. 
I
n many countries, vaccines against some human papil-
lomavirus (HPV) types are now administered to girls 
and young women with the goal of protecting them against 
HPV-induced cervical cancer (1,2). The introduction of 
HPV vaccines has also drawn more attention to the fact that 
HPV is associated not only with cervical cancer and genital 
warts but also with other tumors, such as head neck and 
anogenital cancers (3). We focus on the role of HPV in the 
increased incidence of oropharyngeal squamous cell carci-
noma (OSCC), the head and neck cancer in which HPV is 
most commonly found (4).
Head and neck cancer most commonly is of the 
squamous cell carcinoma type (HNSCC) and includes 
cancers of the oral cavity, oropharynx, hypopharynx, lar-
ynx, sinonasal tract, and nasopharynx. HNSCC is the sixth 
most common type of cancer in the world; almost 600,000 
cases are reported annually, and of these, ≈10% (or more 
for some geographic locations) are OSCC (5). Globally, the 
incidence and localization of HNSCC varies widely. It is 
the most common form of cancer in India, and incidence 
is higher in countries in Latin America than in the United 
States and northern Europe. In addition, men are generally 
more often affected than women. Smoking, alcohol con-
sumption, and betel chewing are traditional risk factors for 
HNSCC and OSCC (6). However, during the past decade 
several reports have documented HPV in OSCC (7–9). 
HPV infection, with dominance of HPV16 infection, has 
therefore been acknowledged by the International Agency 
for Research against Cancer as a risk factor for OSCC (10). 
Moreover, there are accumulating reports from many coun-
tries that the incidence of OSCC is increasing. We suggest 
that this increase is caused by a slow epidemic of HPV 
infection–induced OSCC.
OSCC
Tonsillar cancer is the most common OSCC, followed 
by base of tongue cancer. Together, these 2 cancers ac-
count for 90% of all OSCCs (6,9). Patients usually do not 
seek counseling until the tumors are large because small 
tumors cause little distress and may not be noticed by the 
patient. Curative treatment implies surgery, radiotherapy, 
and chemotherapy; the goal is to cause as little functional 
and cosmetic damage as possible (6,9). If a cure cannot be 
obtained, palliative therapy is given to treat pain and dis-
comfort. Similar to HNSCC, in general, survival rates for 
patients with OSCC are poor. Patients with OSCC have an 
overall 5-year survival rate of ≈25% (6,9). Furthermore, 
even when standardized treatment is used and tumors are 
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at the same stage and have similar histologic features, it 
is difﬁ  cult to predict the outcome. Several reports now de-
scribe the incidence of OSCC as increasing and indicate 
that HPV-positive OSCC has a better clinical outcome than 
HPV-negative OSCC (7–9,11–19). Thus, predictive and 
prognostic markers would be of clinical value for preven-
tion and treatment of OSCC. 
HPV
There are >100 HPV types, some found in skin warts 
and others in mucous tissues, and the association of dif-
ferent HPV types with cervical, some anogenital, and 
head and neck cancers is well established (3). The 8-kb, 
double-stranded, circular DNA HPV genome, enclosed in 
a 52–55 nm viral capsid, codes for the L1 and L2 viral 
capsid proteins and for the E1–E2 and E4–E7 proteins, 
which play major roles in gene regulation, replication, 
pathogenesis, and transformation (3). In high-risk HPVs 
(i.e., those that are more likely to cause lesions that may 
develop into cancer [www.cancer.gov/cancertopics/fact-
sheet/Risk/HPV]), E6 and E7 deregulate cell cycle con-
trol by E6 binding and degradation of p53, and E7 binds 
and inhibits the function of the retinoblastoma protein 
(Rb) (3). The L1 protein can self-assemble into virus-like 
particles, which form the basis of both currently approved 
vaccines against HPV infection (1–3).
HPV and Methods for Detection in OSCC
During the past few decades, HPV DNA has been 
detected in ≈25% of HNSCCs overall, but especially in 
OSCC, for which 45%–100% cases were reported to be 
HPV positive (7–9,11–19). The latter variation may de-
pend on OSCC location, the type of specimens available, 
the techniques used for testing, and the time period and 
country from which the sample material was obtained 
(7–9,11–19).
Analysis of HPV DNA was (and still is) performed 
primarily by using formalin-ﬁ  xed, parafﬁ  n-embedded tis-
sue, in which the DNA can be partially degraded. It is now 
widely accepted that it is easier to detect longer HPV DNA 
fragments in fresh or fresh-frozen material, although newer 
techniques are more sensitive. Many early studies during 
the 1980s were based on Southern blot techniques or in situ 
hybridization for detection of HPV.
Since the 1990s, virology laboratories used PCR for 
detection of HPV DNA (20–23). Screening for HPV was 
initially performed by using general PCR primers for HPV, 
which enabled detection of several HPV types (21–23). 
PCR of a control cellular gene was used to assess the DNA 
quality of samples. These techniques are robust and are still 
used but need additional methods for HPV typing. There 
are now many other methods that directly determine the 
presence of several different HPV types. The Food and 
Drug Administration–approved Hybrid Capture II (Digene 
Corporation, Gaithersburg, MD, USA) detects 5 low-risk 
and 13 high-risk HPV types and uses the fact that HPV 
DNA hybridizes with synthetic RNA probes complemen-
tary to DNA sequences from speciﬁ  c HPV types (20). An 
assay used in several studies, the Roche (Basel, Switzer-
land) linear array HPV Genotyping Test, detects 37 HPV 
types and is based on a method developed by Gravitt et al. 
(24). In this method, HPV PCR products are hybridized to a 
linear array of type speciﬁ  c probes. Recently, Schmitt et al 
developed a sensitive bead-based multiplex method, origi-
nally set up for 22 different HPV types but later expanded, 
in which HPV PCR products are coupled to type-speciﬁ  c 
probes on beads and analyzed by using Luminex (25).
To assay for biologic activity of HPV in tumors, analy-
sis of E6 and E7 expression by detecting E6 and E7 mRNA 
by reverse transcription followed by real-time PCR is also 
often performed (13). In pathology departments, HPV 
screening is often conducted by in situ hybridization, and 
in some instances p16 immunohistochemical analysis is 
used as a substitute to assay for biologically active HPV 
because there is a correlation between the presence of HPV 
and overexpression of p16 (26,27).
HPV in OSCC 
When HPV in OSCC became more obvious, several 
studies concentrated on characterizing HPV-positive OSCC 
(4,7–9,11–19). HPV type 16 was highly prevalent (≈90%) 
in OSCC in all studies; other HPV types (e.g., HPV-31, 
-33, -58, -59, -62, and -72) were less common, and HPV 
was demonstrated to be episomal or integrated into the cel-
lular genome (14,28).
In several studies, E6 and E7 expression in OSCC were 
shown, suggesting that HPV was actively involved in the 
etiology of the tumors (13). In addition, the association of 
p16 overexpression with HPV was a further indicator of ac-
tive E7 because of E7-induced cell cycle activation and up-
regulation of p16 by inactivating the Rb pathway (3,26,27). 
HPV-positive tumors were also less likely to have mutated 
p53 (7) and were more frequently aneuploid and less dif-
ferentiated than HPV-negative tumors (29). Furthermore, 
comparative genomic hybridization indicated that HPV-
positive tonsillar cancer, in contrast to HPV-negative can-
cer, often showed chromosome 3q ampliﬁ  cation similar to 
that in HPV-positive cervical and vulvar cancer, which fur-
ther supports the oncogenic role of HPV in OSCC (30).
It was also observed that patients with HPV-positive 
OSCC were younger and lacked the traditional risk factors 
of smoking and alcohol consumption (7–9,13,17). More-
over, a major feature, noted in several studies, was that 
HPV was a favorable prognostic factor for clinical outcome 
of OSCC, as demonstrated in Figure 1 (7–9,11–19). This 
ﬁ  nding was independent of tumor stage, age, gender, grade 
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of differentiation, p53 immunohistochemical results, or 
DNA ploidy (7–9). However, Lindquist et al. (13) observed 
that patients with HPV-positive tonsillar cancer who had 
never smoked had a better prognosis than those who were 
smokers, and this observation was recently conﬁ  rmed by 
Ang et al. (16). The reasons for this ﬁ  nding are most likely 
complex and should be investigated further. One could 
speculate, for example, that HPV induces an immune re-
sponse and that smoking abrogates this response. A differ-
ent option is that smoking and HPV in combination induce 
a different category of tumors and that smoking induces 
additional genetic alterations in these tumors, as was also 
suggested by Ang et al. (16).
In general, the prognostic value of HPV status is for 
OSCC and not for HNSCC. In some studies with conﬂ  ict-
ing ﬁ  ndings, the prognostic value of HPV was determined 
for all HNSCC anatomic sites (9). However, because there 
are differences in survival rates and presence of HPV at 
different locations, even for OSCC, studies should be per-
formed per location.
In summary, the accumulated data suggest different 
entities of OSCC, where some primarily depend on smok-
ing and alcohol and others on HPV infection. It is also 
likely that there are combined etiologies. Nevertheless, pa-
tients with HPV-positive OSCC consistently have a better 
prognosis (7–9,11–19).
An HPV-induced Epidemic of OSCC
We suggest the increased incidence of OSCC depends 
on HPV infection and results in an increased proportion 
of HPV-positive OSCCs. During the past decades, studies 
from the United States, Finland, Sweden, the Netherlands, 
the United Kingdom, and Scotland showed an increase in 
the incidence of OSCC, tonsillar cancer, and base of tongue 
cancer (31–36). In addition, during the past 10 years, an 
increase in the proportion of HPV-positive OSCC has been 
reported, and we speculate that this is not caused simply 
by use of more sensitive diagnostic techniques. In many 
of these studies the same assay was used when studying 
OSCC over time (12,18,19). Furthermore, the general PCR 
ampliﬁ  ability of the DNA from the older tested samples 
was also validated.
Using the Swedish Cancer Registry, which covers ba-
sically all cancer cases in Sweden for 1970–2002, we dis-
closed a 2.8-fold increase (2.6-fold for men and 3.5-fold for 
women) in the incidence of tonsillar cancer in the Stock-
holm area (12), where 25%–30% of all patients in Sweden 
with tonsillar cancer are treated. In parallel, we examined 
all 237 available samples from the 515 patients with tonsil-
lar cancer in Stockholm during the same period and found a 
2.9-fold increase in the proportion of HPV-positive tonsil-
lar cancer from 23% to 68% (12). We thus suggested HPV 
infection played a role in the increase of this disease (12).
In continuation of the above study, we followed the 
incidence of tonsillar and base of tongue cancer in Stock-
holm in the Swedish Cancer Registry and demonstrated 
a substantial increase for both tumor types during 1970–
2006, as shown in Figure 2 (18,19,34). We then performed 
a follow-up study in the Stockholm area of the prevalence 
of HPV in tonsillar cancer during 2003–2007; using the 
Swedish Cancer Registry, we identiﬁ  ed 120 patients (18). 
Using the same methods as in the ﬁ  rst study, we found that 
the proportion of HPV-positive cancers in the 98 available 
pretreatment biopsy specimens had signiﬁ  cantly increased 
both from 1970 through 2007 (p<0.0001) and from 2000 
through 2007 (p<0.01). During the last 2 years of the study 
(2006–2007), 93% of all tonsillar cancer was HPV posi-
tive. Moreover, the incidence of HPV-positive tumors al-
most doubled each decade during 1970–2007, indicating a 
7-fold increase over the whole period; in parallel, a decline 
of HPV-negative tumors was observed (Figure 3).
Shortly afterwards, we demonstrated that the preva-
lence of HPV-positive base of tongue cancer also had 
increased in the Stockholm area during 1998–2007 (19). 
When we analyzed 95 pretreatment biopsy specimens from 
base of tongue SCC from the 109 patients reported dur-
ing 1998–2007 in the Swedish Cancer Registry in a similar 
way as above, we found an increase in the proportion of 
HPV-positive tumors from 54% in 1998–1999 to 84% in 
2006–2007.
The strength of the above studies is that the Swedish 
Cancer Registry covers all cancer cases in Sweden and that 
we have analyzed all available pretreatment diagnostic bi-
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Figure 1. Survival rates for patients with human papillomavirus 
(HPV)–positive tonsillar cancer compared with those for patients 
with HPV-negative cancer. Circles indicate patients who died of 
tonsillar cancer during the follow-up period; plus signs indicate 
patients who were removed from the study for other reasons (e.g., 
died from a cause other than tonsillar cancer, left the country); 
p<0.0005. Data from Lindquist et al. (13), with permission of 
Elsevier (www.elsevier.com).SYNOPSIS
opsy specimens for HPV. The limitation of our study is that 
Sweden is a small country with only 9 million inhabitants.
Covering almost the same time period as above, 
Chaturvedi et al. reported an increase in the proportion of 
potentially HPV-related OSCC in the United States (35). 
However, the previous year, Sturgis and Cinciripini had al-
ready proposed a possible emerging epidemic of HPV-as-
sociated cancers (11). More recently, Marur et al. reviewed 
many studies, further supporting an increase in OSCC (17). 
Notably, it was also suggested that the increase in OSCC 
occurs mainly in men (17). However, using the Swedish 
Cancer Registry, in the Stockholm area, Hammarstedt et 
al. observed also an increase of OSCC in women (12). It is 
necessary to acknowledge that the numbers of women with 
OSCC are more limited and that it could be more difﬁ  cult 
to identify major changes in this group. 
The possible causes for this increase have been dis-
cussed extensively and have focused on changes in sexual 
patterns, such as increased oral sex or increasing numbers 
of sex partners. A signiﬁ  cant association has been shown 
between HPV-positive tonsillar cancer and early initial sex 
or number of oral or vaginal sex partners (37).
Furthermore, in a recent study by D’Souza et al., it 
was shown that the risk of developing oral HPV infection 
increased with increases in lifetime oral or vaginal sex part-
ners (38). It has also been reported that not only oral sex, 
but also open-mouthed kissing, was associated to the devel-
opment of oral HPV infection (38). In this study, 2 study 
populations were included, one (332 patients) consisted of 
a control patient group >18 years of age from the Johns 
Hopkins outpatient otolaryngology clinic (2000–2006) en-
rolled in 2 case–control studies within a prospective co-
hort with HNSCC. The other (210 students) consisted of 
students >17 years of age recruited from the campuses of 
Towson University and the University of Maryland in 2007. 
The latter study may have had some limitations because it 
was not population based, and data for open-mouthed kiss-
ing for control patients and smoking for college students 
were absent. Nevertheless, this study suggests that oral-to-
oral contact may play a role for oral HPV transmission and 
could play a major role in timing of prophylactic vaccina-
tion of children.
Several reports show an increase in OSCC and the pro-
portion of HPV-positive OSCC and an association of the 
latter to early sex debut and many partners. Thus, we sug-
gest that we are encountering a slow epidemic of mainly 
sexually transmitted HPV-induced OSCC. 
HPV in OSCC and Consequences 
for Treatment and Prevention
The possibility that we are dealing with an HPV-induced 
epidemic of OSCC warrants special attention. For example, 
in Stockholm, the incidence of HPV-positive tonsillar cancer 
has increased 7-fold over 30 years (18). OSCC now accounts 
for approximately one third of all HNSCC cases annually 
in Sweden. The fact that HNSCC in general is decreasing, 
and OSCC is increasing, may in 10 years result in OSCC 
accounting for half of all HNSCCs in Sweden, and similar 
trends are likely elsewhere, e.g., the United States, United 
Kingdom, the Netherlands, and Finland. It is also known 
that patients with HPV-positive OSCC are younger and have 
a better prognosis than HNSCC patients and patients with 
HPV-negative OSCC (7,8). In contrast, because of the poor 
prognosis for HNSCC and, in the past for OSCC, therapeu-
tic measures have recently been intensiﬁ  ed with induction 
chemotherapy, hyperfractionated radiotherapy, surgery, and 
occasional use of epidermal growth factor receptor inhibi-
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Figure 2. Age-standardized incidence of tonsillar and base of 
tongue cancers, Stockholm, Sweden, 1970–2006.
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Figure 3. Estimated age-standardized incidence of human 
papillomavirus (HPV)–positive and HPV-negative tonsillar 
cancer squamous cell carcinoma cases per 100,000 person-
years, Stockholm, Sweden, 1970–2006. Error bars indicate 95% 
conﬁ  dence intervals. Data from Näsman et al. (18), with permission 
of John Wiley and Sons (www.interscience.wiley.com).Oropharyngeal Cancer Epidemic and HPV
tors. This intensiﬁ  ed therapy results in more severe acute 
and chronic side effects, such as difﬁ  culties in swallowing 
or talking, dry mouth, and necrosis of the jawbone, and is 
also more expensive for society. Accordingly, it is possible 
that increasing numbers of OSCC patients with a better prog-
nosis are being treated with intensiﬁ  ed therapy. As a result, 
many patients have substantial chronic unnecessary side ef-
fects. It is therefore necessary to identify which patients need 
and which do not need intensiﬁ  ed treatment, both to increase 
patient survival times and quality of life and for the socio-
economic beneﬁ  t of society.
Several reports have been published and other studies 
are ongoing to assess which molecular factors, such as p16, 
p53, and others, besides the presence of HPV in OSCC, can 
best predict clinical outcome and which treatments are opti-
mal according to the same predictive markers (7–9,17,26). 
Some retrospective reports have suggested that persons 
with HPV-positive OSCC have higher response rates to 
chemotherapy and radiation; however, in other reports this 
has not been conﬁ  rmed (9,17). A recent study also observed 
that tumor HPV status is a strong independent prognos-
tic factor for survival among patients with HPV-positive 
OSCC irrespective of treatment (16). However, in the same 
study, among patients with HPV-positive tumors, the risk 
for death signiﬁ  cantly increased with each additional pack-
year of smoking, independent of treatment modality (16), a 
result similar to that found by Lindquist et al. (13).
It has been shown in an experimental setting that HPV-
positive tumors were not more curable on the basis of in-
creased epithelial sensitivity to cisplatin or radiation thera-
py (39). Instead, Spanos et al. demonstrated that radiation 
and cisplatin induced an immune response to this antigenic 
type of cancer. This ﬁ  nding could suggest that the presence 
of HPV in a tumor induced by smoking could be of ben-
eﬁ  t, but it is possible that smoking also may abrogate the 
immune response. As mentioned, the relationship between 
smoking and HPV and their roles in OSCC is most likely 
complex. In future studies, it would therefore be valuable to 
obtain more molecular and immunologic information and 
to determine if it is a survival beneﬁ  t to stop smoking dur-
ing and after therapy.
Summarizing treatment of OSCC patients, it is ob-
vious that additional information will be required before 
it will be possible to guide treatment decisions for the 
individual patient on the basis of HPV status. Neverthe-
less, there is accumulating evidence that HPV status and 
overexpression of p16, and having never smoked, is of 
beneﬁ  t. Future prospective clinical studies, including di-
agnostics of HPV, molecular and immunologic proﬁ  les, 
history of smoking, cessation of smoking during therapy, 
and effects of different treatment modalities and their side 
effects on quality of life, will be of beneﬁ  t for personal-
ized treatment.
Finally, it is also essential to keep in mind that we now 
have vaccines directed against HPV16, which accounts for 
≈80%–90% of all HPV-positive OSCC, at least in Europe 
and the United States (7–9,11–9). Although it will likely 
take several decades before the effects of HPV vaccination 
on cancer incidence will be detected, it is crucial to moni-
tor the effects of the present HPV vaccination, not only on 
the incidence of cervical cancer but also on the incidence 
of OSCC.
Few if any of other studies have focused on perform-
ing isolated health economic analysis of the effect of HPV 
on OSCC. However, a recent study pointed out that there is 
an improvement of the present cost-effectiveness of HPV 
vaccines when the effects on other HPV-associated tumors 
cancers are included (40). Furthermore, in countries with 
effective cervical cancer screening programs, other HPV-
associated noncervical cancers represent a relatively high 
proportion of HPV-positive cancers (15). Considering that 
OSCC is the second most common HPV-associated cancer 
and its incidence is increasing, the effect of the HPV vac-
cine on this tumor deserves attention, and we need to know 
if future vaccination against HPV infection should include 
both women and men.
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